Radiopharm Theranostics tanks on ASX debut – The Australian Financial Review

The early stage company does not have revenue from licence arrangements or product sales. It is developing a platform of radiopharmaceutical products for diagnostic and therapeutic cancer treatment.
Shanghai-based NanoMab Technologies is the second-largest…

Click here to view the original article.